Saracatinib (AZD0530)

10 mg

Cat. No.: 12-B11

$99.00

Saracatinib is a highly selective, orally available Src/Abl kinase inhibitor.  It is highly selective for Src and Abl kinases against a large range of tyrosine and serine-threonine kinases (VEGFR, FGFR, c-Kit etc,) Saracatinib exerts its activity through ATP competitive and reversible inhibition  of the target enzyme. Saracatinib has been shown to inhibit tumor growth in a manner independent of dose and inhibits phosphorylation of focal adhesion kinase (FAK) and paxillin in a dose-dependent manner in a Calu-6 Xenograft model.

 

Categories: ,

Details

TECHNICAL INFORMATION

Other Names: AZD0530

Chemical Formula:  C₂₇H₃₂ClN₅O₅ 

CAS Number: 379231-04-6

Molecular Weight: 542.03

Purity:  >98%

Appearance:  a crystalline solid 

Solubility: DMSO

 

STORAGE AND HANDLING

Storage: Store at 4°C and protected from light. Following reconstitution, store  aliquots at -20°C. 

Stability: Stock solutions stable at -20°C for up to 2 years.

Shipping Conditions: Shipped at room temperature.

 

PRODUCT USE

Soluble in DMSO at 200 mg/ml. If precipitate is observed,  vortex for 5 minutes.

 

References

Hennequin et al. (2006) N-(5-chloro-1 | 3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine | a novel | highly selective | orally available | dual-specific c-Src/Abl kinase inhibitor. J Med Chem. 49(22):6465-88.

Green et al. (2009) Preclinical anticancer activity of the potent | oral Src inhibitor AZD0530. Mol Oncol. 3(3):248-61

Rajeshkumar et al. (2009) Antitumor effects and biomarkers of activity of AZD0530 | a Src inhibitor | in pancreatic cancer. Clin Cancer Res. 15(12):4138-46.

Tech Docs

Product Specifications

MSDS

Related products